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Abstract
Background and Purpose—Numerous case reports describe stroke in individuals with sickle
cell trait (SCT) in the absence of traditional risk factors for cerebrovascular disease. To date, no
prospective epidemiological studies have investigated this association.
Methods—A population-based sample of African Americans (N=3,497, mean age=54,
female=62%) was followed from 1987–2011 in the Atherosclerosis Risk in Communities Study
(ARIC), contributing a total of 65,371 person-years. Hazard ratios and incidence rate differences
for ischemic stroke were estimated, contrasting SCT to homozygous hemoglobin A (HbAA).
Models were adjusted for age, sex, smoking, diabetes, hypertension, total cholesterol, atrial
fibrillation, and coronary heart disease.
Results—SCT was identified in 223 (6.4%) participants. Over a median follow up of 22 years,
401 subjects experienced incident stroke (89% ischemic). Incident ischemic stroke was more
frequent among those with SCT (13%) than HbAA (10%). SCT was associated with an ischemic
stroke hazard ratio of 1.4 (1.0 – 2.0), and an incidence rate difference amounting to 1.9 (0.4 – 3.8)
extra strokes per 1000 person-years.
Conclusion—We observed an increased risk of ischemic stroke in African Americans with SCT.
Further investigation of the incidence and pathophysiology of stroke in SCT patients is warranted.
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African Americans are disproportionately burdened by cerebrovascular disease. The
prevalence of stroke in African Americans 18 years or older is nearly twice that of non-
Hispanic whites (4.0% vs. 2.3%)1. Although stroke incidence has been decreasing since the
1990s for whites, this trend has not been observed in African Americans1. Stroke incidence
is not only higher in African Americans, it occurs at a younger age, resulting in substantial
morbidity with direct and indirect costs2. Traditional risk factors explain much of the
disparity in stroke outcomes for African Americans; however, genetics likely have a role.
Sickle cell trait (SCT), the heterozygous carrier state of sickle cell anemia, is a debated risk
factor for stroke3,4. With a heterozygous allelic frequency of 7 – 9% in African Americans,
and 0.2% in non-Hispanic whites5, SCT is estimated to affect over 3 million Americans. The
correlation between sickle cell anemia and stroke is well known6; however, increasing
evidence suggests the heterozygous carrier state may be associated with thromboembolism7,
a potential cause of stroke. Additionally, numerous case reports describe stroke in young
individuals with SCT, in the absence of traditional risk factors8–11. Intrigued by these
findings, we conducted a prospective epidemiological investigation of SCT and ischemic




Initiated in 1987, the ARIC study is an ongoing epidemiological cohort representing 4 U.S.
areas. Along with white study participants recruited from Minneapolis, Minnesota and
Washington County, Maryland, a population-based sample (N= 4,270) of African
Americans aged 45–64 was recruited with written informed consent, from Jackson,
Mississippi and Forsyth County, North Carolina12. The ARIC study encompasses 5 cohort
examinations, with annual telephone surveys during interim years and ongoing surveillance
of hospitalized events. Study participant retention has been excellent, with 94% of survivors
participating in the annual survey in 2010. All study protocols were approved by the
University of Mississippi and Wake Forest University Institutional Review Boards.
Genotyping
Genotyping was performed using functionally tested TaqMan® SNP Genotyping Assays in
accordance with manufacturer protocols (Life Technologies, Grand Island, NY).
Hemoglobin S was identified from biallelic variation [missense change (Glu7Val)] in the
single nucleotide polymorphism rs334, using the following custom primer and probe
sequences: Forward-TCAAACAGACACCATGGTGCAT, Reverse-
CCCCACAGGGCAGTAACG, VIC-CTGACTCCTGAGGAGAA-MGB, 6FAM-
CTGACTCCTGTGGAGAA-MGB. Hemoglobin C was identified from single nucleotide
polymorphism rs33930165 [missense change (Glu7Lys)], using custom primer and probe
sequences: Forward-AAACAGACACCATGGTGCATCT, Reverse-
CCCCACAGGGCAGTAACG, VIC-CAGACTTCTCCTTAGGAGTC-MGB, 6FAM-
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ACTTCTCCTCAGGAGTC-MGB (designed on the complement strand). For quality
assurance, blind duplicate genotyping of hemoglobin S and hemoglobin C was performed in
a random sample representing 5% of the total assays (kappa coefficients 0.83 and 0.93,
respectively).
Ancestry and Relatedness
Ancestry was quantified using EIGENSTRAT 5.0.1 (David Reich, open source), based on
genomic variation characterized by the HumanExome BeadChip v1.0 (Affymetrix, Santa
Clara, CA), as previously described13. First degree relatives were identified by PLINK
(Shaun Purcell, http://pngu.mgh.harvard.edu/purcell/plink)14. Relatedness pairs were broken
by randomly dropping one first degree relative from each set, irrespective of SCT status or
stroke outcomes.
Stroke History
History of stroke was ascertained at the study baseline by self-reported signs and symptoms.
Based on the responses, a computer algorithm diagnosed stroke, and determined the vascular
distribution involved15. The algorithm performance was previously validated, classifying
prevalent stroke with a sensitivity of 87.8% and a specificity of 71.9%16.
Incident Stroke
Incident stroke over the course of follow up was captured by hospital surveillance, as
previously described17. Medical records from hospitalizations with diagnosis codes 430–438
and neurological deficits exceeding 24 hours were abstracted for physician review. Stroke
diagnosis was verified by the discharge summary, imaging reports, neurological consults,
and medical history, and categorized as either definite or probable17. For quality assurance,
diagnoses were also determined by a computer algorithm. Any disagreements between the
physician diagnosis and computer algorithm were adjudicated by a second physician
reviewer. Agreement rates between the physician reviewer and computer algorithm were
78%17. In the majority of discordant diagnoses (65%), the physician adjudicator agreed with
the physician reviewer, rather than the computer algorithm17.
Clinical Covariates
Medical histories and clinical covariates were ascertained at the study baseline, by home
interviews, health questionnaires, and clinical examinations. Age, sex, race, and current
smoking were self-reported. Seated blood pressures were measured by random-zero mercury
manometers. Hypertension was considered a systolic blood pressure ≥ 140 mmHg, a
diastolic blood pressure ≥ 90 mmHg, or antihypertensive medication use. Fasting cholesterol
and glucose were assessed by ARIC central laboratories. Hypercholesterolemia was
considered a total fasting cholesterol ≥ 6.2 mmol/L. Diabetes was defined by a fasting blood
glucose level ≥ 7 mmol/L, non-fasting blood glucose ≥ 11.1 mmol/L, self-reported diabetes,
or use of diabetic medications. Standardized, 12-lead electrocardiograms were performed,
and assigned a Minnesota code18 by the ARIC ECG Reading Center. Atrial fibrillation was
identified by a Minnesota code of 8.3.1. Prevalent coronary heart disease was defined by
self-report, history of myocardial infarction, coronary artery bypass graft, or percutaneous
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coronary intervention; or electrocardiogram (ECG) suggestive of prior myocardial
infarction.
Final study population
A total of 4,151 African Americans were genotyped for hemoglobin S and hemoglobin C.
After excluding first degree relatives (N=253), those with missing or inadequate genotype
calls (N=33), participants identified with hemoglobin C trait (N=88), hemoglobin C disease
(N=2), hemoglobin SC disease (N=5), or sickle cell anemia (N=3), and those with missing
clinical covariates (N=270), a total of 3,497 remained.
Statistical Analysis
All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Categorical variables
were compared by a χ2 test and continuous variables compared by ANOVA. Categorical
variables with expected cell counts < 5 were analyzed using Fisher’s exact test. Stroke
hazard ratios contrasting SCT to HbAA were calculated with Cox regression, adjusting for
the traditional risk factors for stroke (age, sex, smoking, diabetes, hypertension, total
cholesterol, atrial fibrillation, and coronary heart disease). In a separate model, the effect of
genetic admixture was examined, by including 10 ancestral principal components in the
adjusted Cox regression model. Proportional hazards assumptions were verified by plotting
Martingale residuals, and assessing deviations of observed suprema from 1000 simulated
paths by Kolmogorov-Smirnov testing19. No Cox models were found to violate proportional
hazards. Stroke incidence rate differences (IRD) were estimated by additive Poisson
regression, adjusted for demographics and the traditional risk factors for stroke. Goodness of
fit was verified by the deviance to degrees of freedom ratio. No Poisson models were found
to be over-dispersed.
Power calculations for stroke hazard ratios were calculated a priori. Based on the previously
reported age-adjusted ischemic stroke incidence rates for ARIC participants aged 45–84
(6.6 / 1000 person-years for African American men, and 4.9 / 1000 person-years in African
American women)20 we estimated an age-adjusted, sex-standardized (38% men, 62%
women) reference rate of 5.55 strokes / 1000 person-years. With an assumed sample size of
3,200 and SCT prevalence of 8%, we expected 80% power to detect a hazard ratio of 1.5,
with significance at α=0.05 (2-sided).
Results
In the final study population (N=3,497) of African Americans, 223 (6.4%) were identified
with SCT, which was similarly prevalent (7.2%) among those excluded for missing
covariates or relatedness. The mean age at the study onset was 54, and 62% were female.
Study participants with SCT were less often smokers, but had a higher prevalence of
hypercholesterolemia. Otherwise, cerebrovascular risk factors at the study baseline did not
differ by SCT classification (Table 1). History of stroke was prevalent in 70 (2%) and was
similar among participants with SCT and HbAA genotypes; however, baseline neurological
histories were missing for 737 (21%).
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Study participants were prospectively followed a median of 22 (15 – 23) years, contributing
to a total of 65,371 person-years. Over this time frame, 401 experienced a stroke. The
majority of strokes, 355 (89%) were ischemic, and of these 76% were considered definite.
The overall frequency of ischemic stroke (10%) was similar in those excluded for missing
covariates or relatedness (9%). Among study participants with SCT, 29 (13%) experienced
incident ischemic stroke, compared to 326 (10%) of those with HbAA. The mean age at
incident ischemic stroke was 67 ± 7 years, and did not differ by SCT status. The crude
incidence rate of ischemic stroke was 7.1 strokes per 1000 person-years in participants with
SCT, compared to 5.3 strokes per 1000 person-years in individuals with HbAA (Table 2).
In multivariable regression analysis adjusted for traditional risk factors, the stroke rate
among those with SCT was significantly higher than those with HbAA, resulting in
approximately 2 extra strokes per 1000 person-years (IRD: 1.9, p=0.03). When risk was
analyzed as a relative measure, SCT remained associated with incident ischemic stroke, but
estimates were more marginal (HR: 1.4, p=0.08), as shown in Table 3. When the effect of
admixture was considered by including 10 ancestral principal components in the
multivariable Cox regression model, estimates were unchanged (HR: 1.4, 95% CI: 1.0 –
2.0).
Discussion
This is the first prospective, epidemiological study to examine associations between SCT
and incident stroke. After adjusting for demographics and traditional cerebrovascular risk
factors, we observed a greater ischemic stroke risk in African Americans with SCT,
compared to those with the HbAA genotype.
Several case reports have previously described stroke in individuals with SCT8–11. These are
remarkable in that strokes occurred in children and young adults, with no underlying
traditional risk factors for cerebrovascular disease. However, in large retrospective studies,
associations between SCT and hospital discharge for stroke have been conflicting. The first,
conducted from 1965–1969 at North Carolina Memorial Hospital, included 227 patients
with SCT and 16,701 African Americans assumed to have normal hemoglobin21. No
differences were found in frequency of hospital discharges for stroke; however, African
American controls were never confirmed to have HbAA genotypes, which may have
resulted in substantial misclassification bias.
The second study, conducted in the French Caribbean colony of Guadeloupe, analyzed the
prevalence of SCT in 295 hospitalizations for stroke. Interestingly, a 10-fold higher risk for
hemorrhagic stroke and a 15-fold lower risk for ischemic stroke were observed in patients
with SCT, compared to Guadeloupians with normal hemoglobin22. This study has been
criticized for diagnosing stroke type by computed tomography, which may not distinguish
between primary hemorrhages and hemorrhagic bleeding secondary to infarctions, causing
possible under-diagnosis of ischemic stroke3. It is also uncertain whether the Guadeloupe
population, an admixture of European, African, Indian, and Amerindian ancestries, can be
generalized to African Americans.
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Finally, a recently conducted analysis based on 13,964 African American adults (2,642 with
SCT and 139 with sickle cell anemia) registered with the Kaiser Permanente Northern
California health system reported no differences in stroke diagnoses for patients with either
SCT, sickle cell anemia, or HbAA23. However, the mean age of the study population was
only 35. In adult populations, only pregnant African American women are routinely tested
for sickle hemoglobinopathies, and if positive, the fathers are tested as well23. Due to the
young age of the study population and low number of ischemic stroke events, this analysis
was inadequately designed to detect differences in stroke prevalence by hemoglobin status.
While studies examining SCT and cerebrovascular disease have been limited, many have
established sickle cell anemia as a risk factor for stroke. Sickle cell anemia is characterized
by hemolysis, acute chest syndrome, and pain; and is further complicated by thrombosis,
microvascular occlusions, vasculopathy, and intimal hyperplasia of the cerebral arteries. In
the Cooperative Study of Sickle Cell Disease, which prospectively followed 4,082 patients,
24% with sickle cell anemia experienced a first stroke by the age of 456. The association
between sickle cell disease and stroke is further confirmed by administrative claims data. In
35–64 year old patients with sickle cell disease, the incidence of ischemic stroke is reported
to be 7.4 per 1000 person years24, much higher than 2.7 per 1000 person years for 35–64
year old African Americans overall25. These estimates yield a stroke incidence rate ratio of
2.7, and an incidence rate difference of 4.7 strokes per 1000 person-years; however, it is
noteworthy that the reference group of African Americans from the general population
includes individuals with SCT.
Even in heterozygous carriers, hemoglobin S is associated with hypercoagulability, which
may be an etiologic pathway to stroke. Under conditions of exertion, dehydration, and high
altitude, SCT erythrocytes are known to sickle and polymerize26,27. The sickling
deformation exposes phosphatidylserine on the cell membrane surface, facilitating the
assembly of coagulation enzymatic complexes28. Laboratory assays of healthy individuals
with SCT show elevated markers of coagulation (prothrombin fragment 1+2, thrombin-
antithrombin complex, and d-dimer)29, and epidemiological studies report twice the risk of
pulmonary embolism and venous thrombosis7,30. Increased prevalence of thrombotic
infarctions has also been observed by post-mortem examination. In an autopsy series of 128
SCT patients, obvious visceral infarcts were observed in 18%, but were detected in less than
1% of similarly aged African Americans without SCT31. The spleen was the most common
site of infarction in SCT cases, followed by the kidneys, lung, –and notably– the brain31.
However, autopsy series are based on highly selected populations, and may be subject to
post-mortem artifact.
In addition to hypercoagulability, the SCT phenotype has been associated with cerebral
vasculopathy and subclinical small vessel disease. In a small case-control study examining
children by cerebral MRI, ectasia of the basilar artery was observed in 19%, and white
matter hyperintensities in 10% of children with SCT; yet neither of these findings were
noted in HbAA sibling controls32. Dolichoectasia, characterized by tortuous, dilated vessels
causing bidirectional blood flow, stasis, and thrombus formation, has been associated with
lacunar stroke in the general population33. White matter hyperintensities, often indicative of
cerebral hypoperfusion and axon demyelination, have been correlated with cognitive
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decline34, and future stroke35. The presence of these lesions in children with SCT may
herald future cerebrovascular events. However, to date, no large, epidemiological studies
have examined associations between SCT and cerebral vasculopathy, and these results are
yet to be replicated.
Despite the biological and observational evidence supporting our findings of an association
between SCT and stroke, our analysis has important limitations. Observations were based on
a relatively small number of stroke events in a single cohort, and warrant validation in other
populations. We were also unable to consider rare hemoglobinopathies or sickle beta
thalassemia; however, the likelihood of these genotypes is low. The birth prevalence of
sickle beta thalassemia in African American neonates is reported to be 0.02%, while the
prevalence of compound hemoglobin S with hemoglobin E, or hemoglobin S with
hemoglobin D is reported to be 0.0016% each5. Despite this limitation, the ARIC study is
well suited for the analysis of SCT and stroke, due to the large sample of older African
Americans with extensive genomic characterization, who were prospectively followed for
more than two decades. Phenotypic data was meticulously collected with quality assurance,
and study participant retention was excellent. To ensure the best possible measurement of
exposure, we based our analysis on SCT that was genotyped, rather than imputed. Our
estimations of stroke risk associated with SCT yielded a hazard ratio of 1.4, with a stroke
rate that was 1.9 strokes per 1000 person-years higher than those with HbAA. This seems
plausible, considering the reported stroke hazard ratio associated with sickle cell disease is
2.7 in African American adults, with a stroke rate that is elevated by 4.7 strokes per 1000
person-years. It follows that the stroke risk (if any) associated with SCT would be
attenuated, compared to sickle cell disease.
In conclusion, we observed a greater ischemic stroke risk in African Americans with SCT,
compared to those with homozygous hemoglobin A. If our findings are confirmed by other
studies, further investigation into the pathophysiology of stroke in SCT patients and
potential interventions to mitigate risk would be warranted.
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Table 1




Mean ± SD or No. (%)
HbAA (N=3,274)
Mean ± SD or No. (%) P-value
Demographics
 Age (years) 53 ± 6 54 ± 6 0.7
 Female 113 (63%) 1571 (62%) 0.9
Medical History
 Current smoker 56 (25%) 989 (30%) 0.1
 Hypertension 121 (54%) 1,826 (56%) 0.7
 Hypercholesterolemia 69 (31%) 851 (26%) 0.1
 Diabetes 42 (19%) 642 (20%) 0.8
 Atrial Fibrillation 0 6 (0.2%) 1.0
 Coronary Heart Disease 8 (4%) 133 (4%) 0.7
 Body Mass Index (kg/m2) 30 ± 6 30 ± 6 0.4
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Table 2
Crude incidence rates of ischemic stroke occurring over follow up period (1987–2011), stratified by SCT
status and age at study baseline
Genotype N Strokes Person-years Crude Incidence Rate*
SCT 223 29 4,063 7.1 (5.4 – 9.5)
 < 55 years 134 17 2,659 6.4 (4.5 – 9.0)
 ≥ 55 years 89 12 1,404 8.5 (5.3 – 13.7)
HbAA 3,274 326 61,308 5.3 (4.9 – 5.8)
 < 55 years 1,892 149 38,121 3.9 (3.5 – 4.4)
 ≥ 55 years 1,382 177 23,188 7.6 (6.8 – 8.6)
*
per 1000 person-years
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Table 3
Relative and absolute risks of incident ischemic stroke associated with SCT
Model Adjustments Hazard Ratio Incidence Rate
Difference*
Crude 1.4 (0.9 – 2.0) 1.8 (−0.1 – 2.0)
Age and sex 1.3 (0.9 – 1.9) 2.1 (0.3 – 4.2)




Clinical covariates = smoking, diabetes, hypertension, total cholesterol, atrial fibrillation, and coronary heart disease
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